WHO Gears Up For Reform Driven By Financial Shortfall 25/01/2011 by Catherine Saez, Intellectual Property Watch 4 Comments The Executive Board session of the World Health Organization ended early on Monday after a week of discussions that settled some issues but left some others for the next governing meeting of the organisation in May, with much to do until then. The WHO is facing a significant gap in its budget and a programme of reforms is brewing.
WHO R&D Financing Committee Approved With Controversial Industry Expert 22/01/2011 by Catherine Saez, Intellectual Property Watch 4 Comments World Health Organization members yesterday struck a compromise allowing a Swiss industry representative to sit on a committee selecting proposals for research and developing financing for neglected diseases, disregarding the fact that he is author of one of the proposals. Special safeguards were added to prevent undue influence, but questions remain for some about a conflict of interest.
WHO Members Show Dismay At Delay On Counterfeit Medicines Group 19/01/2011 by Catherine Saez, Intellectual Property Watch 4 Comments World Health Organization members today raised strong concerns that a working group they mandated last May to address problems with WHO policy on counterfeit and substandard medicines has yet to be formed – with four months remaining before it must report back to members. One delegation called for a halt to WHO activities on anti-counterfeiting until the outcome of the working group is accepted by member states.
WHO Future In Question; Debate Over Industry Representation 17/01/2011 by Catherine Saez and William New, Intellectual Property Watch 3 Comments A seemingly overworked and impoverished World Health Organization opened its Executive Board session today with calls for reform amid deep concerns about its financial future. Meanwhile, dissension arose over an industry representative named by the WHO secretariat to a new research and development funding working group, sparking the WHO director general to cast doubt on the role of industry in such groups.
US Supreme Court Expected To Weaken Patent Validity 12/01/2011 by Steven Seidenberg for Intellectual Property Watch 4 Comments Patents will soon receive less protection in the United States. That’s the view of many experts who have been closely following Microsoft Corp. v. i4i Ltd. Partnership, which will be argued before the United States Supreme Court later this year.
Patent Reform, Piracy, Generic Drug Issues Likely For US Congress This Year 11/01/2011 by Liza Porteus Viana, Intellectual Property Watch 1 Comment Although attempts to repeal last year’s healthcare reform bill and efforts to get the deficit under control may take up much of the United States Congress’ time this year, lawmakers are expected to tackle a number of intellectual property-related priorities lawmakers, including patent reform, internet neutrality, and enforcement during the new 112th session.
The 2011 Drug Patent ‘Cliff’ And The Evolution Of IP Valuation 11/01/2011 by Liza Porteus Viana, Intellectual Property Watch 1 Comment In today’s global economy, there is an increasing convergence of intellectual property and finance. Wall Street is grappling with how to recognise the true value of a firm’s intellectual property. Companies are realising that simply accumulating patents does not necessarily increase their firms’ value, but it is how those patents are used that can attract capital. And drug companies facing massive numbers of upcoming patent expiries, a deflated economy and other market pressures, are looking to diversify their portfolios to stay in the black.
The Top Legal IP Issues In The United States In 2011 07/01/2011 by Steven Seidenberg for Intellectual Property Watch Leave a Comment The year 2010 was a turbulent year for intellectual property law in the United States, and 2011 promises more of the same. The following are some of the top US IP developments to watch in the coming year.
Roche Exec Takes Over At Medicines For Malaria Venture 06/01/2011 by William New, Intellectual Property Watch 1 Comment A top Swiss company executive on pandemic influenza and HIV/AIDS research took the reins of the Geneva-based Medicines for Malaria Venture this week, just weeks after MMV was given international organisation status by the Swiss government.
Patent On AIDS Medicine Denied In India; Seen Unlocking Market 04/01/2011 by Catherine Saez, Intellectual Property Watch 2 Comments A decision by the Indian Patent Office to reject a patent on an AIDS drug last week has drawn acclaim from civil society and Indian generic pharmaceutical industries. The decision was not based on a controversial article of Indian law aimed at preventing patent extensions but rather on the grounds of non-inventiveness. Abbott Laboratories, meanwhile, presented Intellectual Property Watch with justification for its Indian patent request.